Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy

Sponsor
Bayer
Study ID
NCT02289924
Status
Completed

Conditions

  • Wet Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The main objectives of this non-interventional cohort field study are to evaluate effectiveness of Eylea and to describe follow-up as well as treatment patterns in patients with wAMD (wet age-related macular degeneration) in routine clinical practice in Italy for a study population of "naïve" patients

Key Dates

Start date
Jan 9, 2015
Status verified
Nov 2023
Primary completion
Mar 28, 2019
Completion
Jul 8, 2019

Study Design

Enrollment
912 participants (actual)

Arms

  • Arm: Cohort 1
    According to the recommendations of the Summary of Product Characteristics (SmPC) in Italy

Primary Outcome Measure

Mean change of visual acuity from baseline to 12 months. [ Time Frame: Baseline to 12 months ]

Related Studies